XELJANZ Drug Insight

“XELJANZ Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) in the 7MM. A detailed picture of the XELJANZ in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain), and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the XELJANZ. The report provides insight about the mechanism of action, dosage, and administration, as well as research and development activity, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments, including the XELJANZ market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about emerging therapies.

Drug Summary

Pfizer markets Tofacitinib under the brand name XELJANZ. It is an inhibitor of JAK, a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) (RA) that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Some of the prominent adverse effects include nausea and headache, as well as more serious immunologic and hematological adverse effects.

It may also be used as an adjunct to methotrexate therapy or other non-biologic disease-modifying antirheumatic drugs (DMARDs) when methotrexate alone is not sufficient. However, it is not recommended in patients who have a history of chronic or recurrent infections or in the presence of an active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster, and urinary tract infections).

Dosage and Administration

The recommended adult daily dosage of XELJANZ and XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, in patients with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia, or anemia.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the XELJANZ description, mechanism of action, dosage and administration, research and development activities in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA).
• Elaborated details on XELJANZ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XELJANZ research and development activity in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) details across the United States, Europe, and Japan.
• The report also covers the patent information and the expiration timeline for XELJANZ.
• The report contains forecasted sales of XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA).
• The report also features the SWOT analysis with analyst views for XELJANZ in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities' websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals, and access to available databases.

XELJANZ Analytical Perspective by DelveInsight

In-depth XELJANZ Market Assessment

This report provides a detailed market assessment of XELJANZ in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) in the 7MM, i.e., the United States, EU4, and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

XELJANZ Clinical Assessment

The report provides the clinical trials information of XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XELJANZ dominance.
• Other emerging products for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA) are expected to give tough market competition to XELJANZ, and the launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of XELJANZ in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA).
• Our in-depth analysis of the forecasted sales data of XELJANZ from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of XELJANZ in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA).

Key Questions

• What is the product type, route of administration, and mechanism of action of XELJANZ?
• What is the clinical trial status of the study related to XELJANZ in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA), and the study completion date?
• What are the key collaborations, mergers, acquisitions, licensing, and other activities related to the XELJANZ development?
• What are the key designations that have been granted to XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA)?
• What is the forecasted market scenario of XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA)?
• What are the forecasted sales of XELJANZ in the 7MM, including the United States, Europe, and Japan? 
• What are the other emerging products available in Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA), and how are they giving competition to XELJANZ for Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA)?
• Which are the late-stage emerging therapies under development for the treatment of Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), and Psoriatic Arthritis (PsA)?